{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:22:05Z","timestamp":1778934125220,"version":"3.51.4"},"reference-count":121,"publisher":"Societatea Romana de Morfologie","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rom J Morphol Embryol"],"published-print":{"date-parts":[[2024,7,19]]},"abstract":"<jats:p>Obesity poses a significant and escalating challenge in contemporary society, increasing the risk of developing various metabolic disorders such as dyslipidemia, cardiovascular diseases, non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and certain types of cancer. The current array of therapeutic interventions for obesity remains insufficient, prompting a pressing demand for novel and more effective treatments. In response, scientific attention has turned to the fibroblast growth factor 21 (FGF21) due to its remarkable and diverse impacts on lipid, carbohydrate, and energy metabolism. This comprehensive review aims to delve into the multifaceted aspects of FGF21, encompassing its discovery, synthesis, functional roles, and potential as a biomarker and therapeutic agent, with a specific focus on its implications for NAFLD.<\/jats:p>","DOI":"10.47162\/rjme.65.2.02","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T08:57:22Z","timestamp":1723021042000},"page":"159-172","source":"Crossref","is-referenced-by-count":10,"title":["The role of FGF21 in the interplay between obesity and non-alcoholic fatty liver disease: a narrative review"],"prefix":"10.47162","volume":"65","author":[{"name":"Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Romania; Doctoral School, University of Medicine and Pharmacy of Craiova, Romania","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina Elena","family":"Negroiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robertina Iulia","family":"Tudora\u015fcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina","family":"Bezn\u0103","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian Ionu\u0163","family":"Ungureanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Doctoral School, University of Medicine and Pharmacy of Craiova, Romania; Emergency County Clinical Hospital, Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sorina Octavia","family":"Hon\u0163aru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Health Care and Physiotherapy, Faculty of Sciences, Physical Education and Informatics, University Center of Pite\u015fti, National University for Science and Technology Politehnica Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzana","family":"D\u0103noiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, Romania; Doctoral School, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"26736","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"\"[1] Hui E, Xu A, Bo Yang H, Lam KS. Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: role of adipokines. J Diabetes Investig, 2013, 4(5):413-425. https:\/\/doi.org\/10.1111\/jdi.12093","DOI":"10.1111\/jdi.12093"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"[2] Polyzos SA, Kountouras J, Mantzoros CS. Obesity and non-alcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism, 2019, 92:82-97. https:\/\/doi.org\/10.1016\/j.metabol.2018.11.014","DOI":"10.1016\/j.metabol.2018.11.014"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"[3] Chen YQ. NASH drug development: seeing the light at the end of the tunnel? J Clin Transl Hepatol, 2023, 11(6):1397-1403. https:\/\/doi.org\/10.14218\/JCTH.2023.00058","DOI":"10.14218\/JCTH.2023.00058"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"[4] Tidwell J, Balassiano N, Shaikh A, Nassar M. Emerging therapeutic options for non-alcoholic fatty liver disease: a systematic review. World J Hepatol, 2023, 15(8):1001-1012. https:\/\/doi.org\/10.4254\/wjh.v15.i8.1001","DOI":"10.4254\/wjh.v15.i8.1001"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"[5] Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell, 2014, 156(1-2):20-44. https:\/\/doi.org\/10.1016\/j.cell.2013.12.012","DOI":"10.1016\/j.cell.2013.12.012"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"[6] Kanneganti TD, Dixit VD. Immunological complications of obesity. Nat Immunol, 2012, 13(8):707-712. https:\/\/doi.org\/10.1038\/ni.2343","DOI":"10.1038\/ni.2343"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"[7] Oh DY, Morinaga H, Talukdar S, Bae EJ, Olefsky JM. Increased macrophage migration into adipose tissue in obese mice. Diabetes, 2012, 61(2):346-354. https:\/\/doi.org\/10.2337\/db11-0860","DOI":"10.2337\/db11-0860"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"[8] Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest, 2003, 112(12):1785-1788. https:\/\/doi.org\/10.1172\/JCI20514","DOI":"10.1172\/JCI20514"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"[9] Sohal A, Chaudhry H, Kowdley KV. Genetic markers predisposing to nonalcoholic steatohepatitis. Clin Liver Dis, 2023, 27(2):333-352. https:\/\/doi.org\/10.1016\/j.cld.2023.01.006","DOI":"10.1016\/j.cld.2023.01.006"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"[10] Montemayor S, Garc\u00eda S, Monserrat-Mesquida M, Tur JA, Bouzas C. Dietary patterns, foods, and nutrients to ameliorate non-alcoholic fatty liver disease: a scoping review. Nutrients, 2023, 15(18):3987. https:\/\/doi.org\/10.3390\/nu15183987","DOI":"10.3390\/nu15183987"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"[11] Polyzos SA, Kountouras J, Mantzoros CS. Adipose tissue, obesity and non-alcoholic fatty liver disease. Minerva Endocrinol, 2017, 42(2):92-108. https:\/\/doi.org\/10.23736\/S0391-1977.16.02563-3","DOI":"10.23736\/S0391-1977.16.02563-3"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"[12] Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in non-alcoholic fatty liver disease. Metabolism, 2016, 65(8):1062-1079. https:\/\/doi.org\/10.1016\/j.metabol.2015.11.006","DOI":"10.1016\/j.metabol.2015.11.006"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"[13] Mota M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism, 2016, 65(8):1049-1061. https:\/\/doi.org\/10.1016\/j.metabol.2016.02.014","DOI":"10.1016\/j.metabol.2016.02.014"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"[14] Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism, 2016, 65(8):1038-1048. https:\/\/doi.org\/10.1016\/j.metabol.2015.12.012","DOI":"10.1016\/j.metabol.2015.12.012"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"[15] Zhang X, Ha S, Lau HCH, Yu J. Excess body weight: novel insights into its roles in obesity comorbidities. Semin Cancer Biol, 2023, 92:16-27. https:\/\/doi.org\/10.1016\/j.semcancer.2023.03.008","DOI":"10.1016\/j.semcancer.2023.03.008"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"[16] Malnick SDH, Ohayon Michael S. The intestinal microbiome and the metabolic syndrome - how its manipulation may affect metabolic-associated fatty liver disease (MAFLD). Curr Issues Mol Biol, 2023, 45(9):7197-7211. https:\/\/doi.org\/10.3390\/cimb45090455","DOI":"10.3390\/cimb45090455"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"[17] Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest, 2005, 115(5):1343-1351. https:\/\/doi.org\/10.1172\/JCI23621","DOI":"10.1172\/JCI23621"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"[18] Tillman EJ, Rolph T. FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases. Front Endocrinol (Lausanne), 2020, 11:601290. https:\/\/doi.org\/10.3389\/fendo.2020.601290","DOI":"10.3389\/fendo.2020.601290"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"[19] Do HT, Tselykh TV, M\u00e4kel\u00e4 J, Ho TH, Olkkonen VM, Bornhauser BC, Korhonen L, Zelcer N, Lindholm D. Fibroblast growth factor-21 (FGF21) regulates low-density lipoprotein receptor (LDLR) levels in cells via the E3-ubiquitin ligase Mylip\/Idol and the Canopy2 (Cnpy2)\/Mylip-interacting saposin-like protein (Msap). J Biol Chem, 2012, 287(16):12602-12611. https:\/\/doi.org\/10.1074\/jbc.M112.341248","DOI":"10.1074\/jbc.M112.341248"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"[20] Ko\u0159\u00ednkov\u00e1 L, Pra\u017eienkov\u00e1 V, \u010cern\u00e1 L, Karno\u0161ov\u00e1 A, \u017delezn\u00e1 B, Kune\u0161 J, Malet\u00ednsk\u00e1 L. Pathophysiology of NAFLD and NASH in experimental models: the role of food intake regulating peptides. Front Endocrinol (Lausanne), 2020, 11:597583. https:\/\/doi.org\/10.3389\/fendo.2020.597583","DOI":"10.3389\/fendo.2020.597583"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"[21] Nati M, Haddad D, Birkenfeld AL, Koch CA, Chavakis T, Chatzigeorgiou A. The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH). Rev Endocr Metab Disord, 2016, 17(1):29-39. https:\/\/doi.org\/10.1007\/s11154-016-9339-2","DOI":"10.1007\/s11154-016-9339-2"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"[22] Boutari C, Perakakis N, Mantzoros CS. Association of adipokines with development and progression of nonalcoholic fatty liver disease. Endocrinol Metab (Seoul), 2018, 33(1):33-43. https:\/\/doi.org\/10.3803\/EnM.2018.33.1.33","DOI":"10.3803\/EnM.2018.33.1.33"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"[23] Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem, 2011, 149(2):121-130. https:\/\/doi.org\/10.1093\/jb\/mvq121","DOI":"10.1093\/jb\/mvq121"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"[24] Salgado JV, Goes MA, Salgado Filho N. FGF21 and chronic kidney disease. Metabolism, 2021, 118:154738. https:\/\/doi.org\/10.1016\/j.metabol.2021.154738","DOI":"10.1016\/j.metabol.2021.154738"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"[25] Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol, 2015, 4(3):215-266. https:\/\/doi.org\/10.1002\/wdev.176","DOI":"10.1002\/wdev.176"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"[26] Ding X, Boney-Montoya J, Owen BM, Bookout AL, Coate KC, Mangelsdorf DJ, Kliewer SA. \u03b2Klotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab, 2012, 16(3):387-393. https:\/\/doi.org\/10.1016\/j.cmet.2012.08.002","DOI":"10.1016\/j.cmet.2012.08.002"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"[27] Kuro-O M. Klotho and endocrine fibroblast growth factors: markers of chronic kidney disease progression and cardio-vascular complications? Nephrol Dial Transplant, 2019, 34(1):15-21. https:\/\/doi.org\/10.1093\/ndt\/gfy126","DOI":"10.1093\/ndt\/gfy126"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"[28] Aaldijk AS, Verzijl CRC, Jonker JW, Struik D. Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho. Front Endocrinol (Lausanne), 2023, 14:1150222. https:\/\/doi.org\/10.3389\/fendo.2023.1150222","DOI":"10.3389\/fendo.2023.1150222"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"[29] Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, Wang L, Goetz R, Mohammadi M, Kuro-o M, Mangelsdorf DJ, Kliewer SA. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol, 2010, 24(10):2050-2064. https:\/\/doi.org\/10.1210\/me.2010-0142","DOI":"10.1210\/me.2010-0142"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"[30] Hultman K, Scarlett JM, Baquero AF, Cornea A, Zhang Y, Salinas CBG, Brown J, Morton GJ, Whalen EJ, Grove KL, Koegler FH, Schwartz MW, Mercer AJ. The central fibroblast growth factor receptor\/beta klotho system: comprehensive mapping in Mus musculus and comparisons to nonhuman primate and human samples using an automated in situ hybridization platform. J Comp Neurol, 2019, 527(12):2069-2085. https:\/\/doi.org\/10.1002\/cne.24668","DOI":"10.1002\/cne.24668"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"[31] Yan F, Yuan L, Yang F, Wu G, Jiang X. Emerging roles of fibroblast growth factor 21 in critical disease. Front Cardiovasc Med, 2022, 9:1053997. https:\/\/doi.org\/10.3389\/fcvm.2022.1053997","DOI":"10.3389\/fcvm.2022.1053997"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"[32] Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta, 2000, 1492(1):203-206. https:\/\/doi.org\/10.1016\/s0167-4781(00)00067-1","DOI":"10.1016\/S0167-4781(00)00067-1"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"[33] Dunshee DR, Bainbridge TW, Kljavin NM, Zavala-Solorio J, Schroeder AC, Chan R, Corpuz R, Wong M, Zhou W, Deshmukh G, Ly J, Sutherlin DP, Ernst JA, Sonoda J. Fibroblast activation protein cleaves and inactivates fibroblast growth factor 21. J Biol Chem, 2016, 291(11):5986-5996. https:\/\/doi.org\/10.1074\/jbc.M115.710582","DOI":"10.1074\/jbc.M115.710582"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"[34] Hsuchou H, Pan W, Kastin AJ. The fasting polypeptide FGF21 can enter brain from blood. Peptides, 2007, 28(12):2382-2386. https:\/\/doi.org\/10.1016\/j.peptides.2007.10.007","DOI":"10.1016\/j.peptides.2007.10.007"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"[35] Suassuna PGA, de Paula RB, Sanders-Pinheiro H, Moe OW, Hu MC. Fibroblast growth factor 21 in chronic kidney disease. J Nephrol, 2019, 32(3):365-377. https:\/\/doi.org\/10.1007\/s40620-018-0550-y","DOI":"10.1007\/s40620-018-0550-y"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"[36] Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, Etgen GJ. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology, 2007, 148(2):774-781. https:\/\/doi.org\/10.1210\/en.2006-1168","DOI":"10.1210\/en.2006-1168"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"[37] Fisher FM, Maratos-Flier E. Understanding the physiology of FGF21. Annu Rev Physiol, 2016, 78:223-241. https:\/\/doi.org\/10.1146\/annurev-physiol-021115-105339","DOI":"10.1146\/annurev-physiol-021115-105339"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"[38] Spann RA, Morrison CD, den Hartigh LJ. The nuanced metabolic functions of endogenous FGF21 depend on the nature of the stimulus, tissue source, and experimental model. Front Endocrinol (Lausanne), 2022, 12:802541. https:\/\/doi.org\/10.3389\/fendo.2021.802541","DOI":"10.3389\/fendo.2021.802541"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"[39] Lundsgaard AM, Fritzen AM, Sj\u00f8berg KA, Myrmel LS, Madsen L, Wojtaszewski JFP, Richter EA, Kiens B. Circulating FGF21 in humans is potently induced by short term overfeeding of carbohydrates. Mol Metab, 2016, 6(1):22-29. https:\/\/doi.org\/10.1016\/j.molmet.2016.11.001","DOI":"10.1016\/j.molmet.2016.11.001"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"[40] S\u00f8berg S, Sandholt CH, Jespersen NZ, Toft U, Madsen AL, von Holstein-Rathlou S, Grevengoed TJ, Christensen KB, Bredie WLP, Potthoff MJ, Solomon TPJ, Scheele C, Linneberg A, J\u00f8rgensen T, Pedersen O, Hansen T, Gillum MP, Grarup N. FGF21 is a sugar-induced hormone associated with sweet intake and preference in humans. Cell Metab, 2017, 25(5):1045-1053.e6. https:\/\/doi.org\/10.1016\/j.cmet.2017.04.009","DOI":"10.1016\/j.cmet.2017.04.009"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"[41] Jin T. Fibroblast growth factor 21 and dietary interventions: what we know and what we need to know next. Med Rev (2021), 2022, 2(5):524-530. https:\/\/doi.org\/10.1515\/mr-2022-0019","DOI":"10.1515\/mr-2022-0019"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"[42] Fazeli PK, Lun M, Kim SM, Bredella MA, Wright S, Zhang Y, Lee H, Catana C, Klibanski A, Patwari P, Steinhauser ML. FGF21 and the late adaptive response to starvation in humans. J Clin Invest, 2015, 125(12):4601-4611. https:\/\/doi.org\/10.1172\/JCI83349","DOI":"10.1172\/JCI83349"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"[43] Maida A, Zota A, Sj\u00f8berg KA, Schumacher J, Sijmonsma TP, Pfenninger A, Christensen MM, Gantert T, Fuhrmeister J, Rothermel U, Schmoll D, Heikenw\u00e4lder M, Iovanna JL, Stemmer K, Kiens B, Herzig S, Rose AJ. A liver stress-endocrine nexus promotes metabolic integrity during dietary protein dilution. J Clin Invest, 2016, 126(9):3263-3278. https:\/\/doi.org\/10.1172\/JCI85946","DOI":"10.1172\/JCI85946"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"[44] Vinales KL, Begaye B, Bogardus C, Walter M, Krakoff J, Piaggi P. FGF21 is a hormonal mediator of the human \"thrifty\" metabolic phenotype. Diabetes, 2019, 68(2):318-323. https:\/\/doi.org\/10.2337\/db18-0696","DOI":"10.2337\/db18-0696"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"[45] Salminen A, Kaarniranta K, Kauppinen A. Integrated stress response stimulates FGF21 expression: systemic enhancer of longevity. Cell Signal, 2017, 40:10-21. https:\/\/doi.org\/10.1016\/j.cellsig.2017.08.009","DOI":"10.1016\/j.cellsig.2017.08.009"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"[46] Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB. FGF-21 as a novel metabolic regulator. J Clin Invest, 2005, 115(6):1627-1635. https:\/\/doi.org\/10.1172\/JCI23606","DOI":"10.1172\/JCI23606"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"[47] Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor-21 regulates PPAR\u03b3 activity and the antidiabetic actions of thiazolidinediones. Cell, 2012, 148(3):556-567. https:\/\/doi.org\/10.1016\/j.cell.2011.11.062","DOI":"10.1016\/j.cell.2011.11.062"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"[48] Chen Z, Yang L, Liu Y, Huang P, Song H, Zheng P. The potential function and clinical application of FGF21 in metabolic diseases. Front Pharmacol, 2022, 13:1089214. https:\/\/doi.org\/10.3389\/fphar.2022.1089214","DOI":"10.3389\/fphar.2022.1089214"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"[49] Straub L, Wolfrum C. FGF21, energy expenditure and weight loss - how much brown fat do you need? Mol Metab, 2015, 4(9):605-609. https:\/\/doi.org\/10.1016\/j.molmet.2015.06.008","DOI":"10.1016\/j.molmet.2015.06.008"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"[50] Staiger H, Keuper M, Berti L, Hrabe de Angelis M, H\u00e4ring HU. Fibroblast growth factor 21 - metabolic role in mice and men. Endocr Rev, 2017, 38(5):468-488. https:\/\/doi.org\/10.1210\/er.2017-00016","DOI":"10.1210\/er.2017-00016"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"[51] Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, Verdeguer F, Wu J, Kharitonenkov A, Flier JS, Maratos-Flier E, Spiegelman BM. FGF21 regulates PGC-1\u03b1 and browning of white adipose tissues in adaptive thermogenesis. Genes Dev, 2012, 26(3):271-281. https:\/\/doi.org\/10.1101\/gad.177857.111","DOI":"10.1101\/gad.177857.111"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"[52] M\u00fcller TD, Tsch\u00f6p MH. Play down protein to play up metabolism? J Clin Invest, 2014, 124(9):3691-3693. https:\/\/doi.org\/10.1172\/JCI77508","DOI":"10.1172\/JCI77508"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"[53] Hill CM, Laeger T, Dehner M, Albarado DC, Clarke B, Wanders D, Burke SJ, Collier JJ, Qualls-Creekmore E, Solon-Biet SM, Simpson SJ, Berthoud HR, M\u00fcnzberg H, Morrison CD. FGF21 signals protein status to the brain and adaptively regulates food choice and metabolism. Cell Rep, 2019, 27(10):2934-2947.e3. https:\/\/doi.org\/10.1016\/j.celrep.2019.05.022","DOI":"10.1016\/j.celrep.2019.05.022"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"[54] Fisher FM, Kim M, Doridot L, Cunniff JC, Parker TS, Levine DM, Hellerstein MK, Hudgins LC, Maratos-Flier E, Herman MA. A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism. Mol Metab, 2016, 6(1):14-21. https:\/\/doi.org\/10.1016\/j.molmet.2016.11.008","DOI":"10.1016\/j.molmet.2016.11.008"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"[55] von Holstein-Rathlou S, BonDurant LD, Peltekian L, Naber MC, Yin TC, Claflin KE, Urizar AI, Madsen AN, Ratner C, Holst B, Karstoft K, Vandenbeuch A, Anderson CB, Cassell MD, Thompson AP, Solomon TP, Rahmouni K, Kinnamon SC, Pieper AA, Gillum MP, Potthoff MJ. FGF21 mediates endocrine control of simple sugar intake and sweet taste preference by the liver. Cell Metab, 2016, 23(2):335-343. https:\/\/doi.org\/10.1016\/j.cmet.2015.12.003","DOI":"10.1016\/j.cmet.2015.12.003"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"[56] Geidl-Flueck B, Hochuli M, Spinas GA, Gerber PA. Do sugar-sweetened beverages increase fasting FGF21 irrespective of the type of added sugar? A secondary exploratory analysis of a randomized controlled trial. Nutrients, 2022, 14(19):4169. https:\/\/doi.org\/10.3390\/nu14194169","DOI":"10.3390\/nu14194169"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"[57] Cyphert HA, Alonge KM, Ippagunta SM, Hillgartner FB. Glucagon stimulates hepatic FGF21 secretion through a PKA- and EPAC-dependent posttranscriptional mechanism. PLoS One, 2014, 9(4):e94996. https:\/\/doi.org\/10.1371\/journal.pone.0094996","DOI":"10.1371\/journal.pone.0094996"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"[58] Lund\u00e5sen T, Hunt MC, Nilsson LM, Sanyal S, Angelin B, Alexson SEH, Rudling M. PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun, 2007, 360(2):437-440. https:\/\/doi.org\/10.1016\/j.bbrc.2007.06.068","DOI":"10.1016\/j.bbrc.2007.06.068"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"[59] Cuevas-Ramos D, Mehta R, Aguilar-Salinas CA. Fibroblast growth factor 21 and browning of white adipose tissue. Front Physiol, 2019, 10:37. https:\/\/doi.org\/10.3389\/fphys.2019.00037","DOI":"10.3389\/fphys.2019.00037"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"[60] Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab, 2007, 5(6):426-437. https:\/\/doi.org\/10.1016\/j.cmet.2007.05.002","DOI":"10.1016\/j.cmet.2007.05.002"},{"key":"ref60","unstructured":"[61] Liu X, Zhang P, Martin RC, Cui G, Wang G, Tan Y, Cai L, Lv G, Li Y. Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice. Am J Cancer Res, 2016, 6(5):1011-1025. https:\/\/e-century.us\/files\/ajcr\/6\/5\/ajcr0031082.pdf"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"[62] Bao L, Yin J, Gao W, Wang Q, Yao W, Gao X. A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway. Br J Pharmacol, 2018, 175(16):3379-3393. https:\/\/doi.org\/10.1111\/bph.14383","DOI":"10.1111\/bph.14383"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"[63] Tezze C, Romanello V, Sandri M. FGF21 as modulator of metabolism in health and disease. Front Physiol, 2019, 10:419. https:\/\/doi.org\/10.3389\/fphys.2019.00419","DOI":"10.3389\/fphys.2019.00419"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"[64] Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, Iglesias R, Gabrielli LA, Sitges M, Giralt M, van Bilsen M, Villarroya F. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun, 2013, 4:2019. https:\/\/doi.org\/10.1038\/ncomms3019","DOI":"10.1038\/ncomms3019"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"[65] Planavila A, Redondo-Angulo I, Ribas F, Garrabou G, Casademont J, Giralt M, Villarroya F. Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc Res, 2015, 106(1):19-31. https:\/\/doi.org\/10.1093\/cvr\/cvu263","DOI":"10.1093\/cvr\/cvu263"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"[66] Joki Y, Ohashi K, Yuasa D, Shibata R, Ito M, Matsuo K, Kambara T, Uemura Y, Hayakawa S, Hiramatsu-Ito M, Kanemura N, Ogawa H, Daida H, Murohara T, Ouchi N. FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism. Biochem Biophys Res Commun, 2015, 459(1):124-130. https:\/\/doi.org\/10.1016\/j.bbrc.2015.02.081","DOI":"10.1016\/j.bbrc.2015.02.081"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"[67] Patel V, Adya R, Chen J, Ramanjaneya M, Bari MF, Bhudia SK, Hillhouse EW, Tan BK, Randeva HS. Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts. PLoS One, 2014, 9(2):e87102. https:\/\/doi.org\/10.1371\/journal.pone.0087102","DOI":"10.1371\/journal.pone.0087102"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"[68] Rosales-Soto G, Diaz-Vegas A, Casas M, Contreras-Ferrat A, Jaimovich E. Fibroblast growth factor-21 potentiates glucose transport in skeletal muscle fibers. J Mol Endocrinol, 2020, 65(3):85-95. https:\/\/doi.org\/10.1530\/JME-19-0210","DOI":"10.1530\/JME-19-0210"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"[69] Lee MS, Choi SE, Ha ES, An SY, Kim TH, Han SJ, Kim HJ, Kim DJ, Kang Y, Lee KW. Fibroblast growth factor-21 protects human skeletal muscle myotubes from palmitate-induced insulin resistance by inhibiting stress kinase and NF-\u03baB. Metabolism, 2012, 61(8):1142-1151. https:\/\/doi.org\/10.1016\/j.metabol.2012.01.012","DOI":"10.1016\/j.metabol.2012.01.012"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"[70] Lin Z, Tian H, Lam KS, Lin S, Hoo RC, Konishi M, Itoh N, Wang Y, Bornstein SR, Xu A, Li X. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab, 2013, 17(5):779-789. https:\/\/doi.org\/10.1016\/j.cmet.2013.04.005","DOI":"10.1016\/j.cmet.2013.04.005"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"[71] Singhal G, Fisher FM, Chee MJ, Tan TG, El Ouaamari A, Adams AC, Najarian R, Kulkarni RN, Benoist C, Flier JS, Maratos-Flier E. Fibroblast growth factor 21 (FGF21) protects against high fat diet induced inflammation and islet hyperplasia in pancreas. PLoS One, 2016, 11(2):e0148252. https:\/\/doi.org\/10.1371\/journal.pone.0148252","DOI":"10.1371\/journal.pone.0148252"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"[72] Johnson CL, Weston JY, Chadi SA, Fazio EN, Huff MW, Kharitonenkov A, K\u00f6ester A, Pin CL. Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. Gastroenterology, 2009, 137(5):1795-1804. https:\/\/doi.org\/10.1053\/j.gastro.2009.07.064","DOI":"10.1053\/j.gastro.2009.07.064"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"[73] Wente W, Efanov AM, Brenner M, Kharitonenkov A, K\u00f6ster A, Sandusky GE, Sewing S, Treinies I, Zitzer H, Gromada J. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1\/2 and Akt signaling pathways. Diabetes, 2006, 55(9):2470-2478. https:\/\/doi.org\/10.2337\/db05-1435","DOI":"10.2337\/db05-1435"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"[74] Kim HW, Lee JE, Cha JJ, Hyun YY, Kim JE, Lee MH, Song HK, Nam DH, Han JY, Han SY, Han KH, Kang YS, Cha DR. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db\/db mice. Endocrinology, 2013, 154(9):3366-3376. https:\/\/doi.org\/10.1210\/en.2012-2276","DOI":"10.1210\/en.2012-2276"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"[75] Crujeiras AB, Gomez-Arbelaez D, Zulet MA, Carreira MC, Sajoux I, de Luis D, Castro AI, Baltar J, Baamonde I, Sueiro A, Macias-Gonzalez M, Bellido D, Tinahones FJ, Martinez JA, Casanueva FF. Plasma FGF21 levels in obese patients undergoing energy-restricted diets or bariatric surgery: a marker of metabolic stress? Int J Obes (Lond), 2017, 41(10):1570-1578. https:\/\/doi.org\/10.1038\/ijo.2017.138","DOI":"10.1038\/ijo.2017.138"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"[76] Berti L, Irmler M, Zdichavsky M, Meile T, B\u00f6hm A, Stefan N, Fritsche A, Beckers J, K\u00f6nigsrainer A, H\u00e4ring HU, de Angelis MH, Staiger H. Fibroblast growth factor 21 is elevated in metabolically unhealthy obesity and affects lipid deposition, adipogenesis, and adipokine secretion of human abdominal subcutaneous adipocytes. Mol Metab, 2015, 4(7):519-527. https:\/\/doi.org\/10.1016\/j.molmet.2015.04.002","DOI":"10.1016\/j.molmet.2015.04.002"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"[77] Zhang X, Yeung DCY, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RLC, Chow WS, Tso AWK, Lam KSL, Xu A. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes, 2008, 57(5):1246-1253. https:\/\/doi.org\/10.2337\/db07-1476","DOI":"10.2337\/db07-1476"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"[78] Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, Badman MK, Martinez-Chantar ML, Maratos-Flier E. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology, 2010, 139(2):456-463. https:\/\/doi.org\/10.1053\/j.gastro.2010.04.054","DOI":"10.1053\/j.gastro.2010.04.054"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"[79] Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, Zhang H, Pan X, Bao Y, Xiang K, Xu A, Jia W. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol, 2010, 53(5):934-940. https:\/\/doi.org\/10.1016\/j.jhep.2010.05.018","DOI":"10.1016\/j.jhep.2010.05.018"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"[80] Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, Celikel CA, Ozdogan O, Imeryuz N, Kalayci C, Avsar E. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest, 2010, 40(10):887-892. https:\/\/doi.org\/10.1111\/j.1365-2362.2010.02338.x","DOI":"10.1111\/j.1365-2362.2010.02338.x"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"[81] Barb D, Bril F, Kalavalapalli S, Cusi K. Plasma fibroblast growth factor 21 is associated with severity of nonalcoholic steatohepatitis in patients with obesity and type 2 diabetes. J Clin Endocrinol Metab, 2019, 104(8):3327-3336. https:\/\/doi.org\/10.1210\/jc.2018-02414","DOI":"10.1210\/jc.2018-02414"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"[82] Marchelek-My\u015bliwiec M, Dziedziejko V, Nowosiad-Magda M, Do\u0142\u0119gowska K, Do\u0142\u0119gowska B, Pawlik A, Safranow K, Wi\u015bniewska M, St\u0119pniewska J, Doma\u0144ski M, Ciechanowski K. Chronic kidney disease is associated with increased plasma levels of fibroblast growth factors 19 and 21. Kidney Blood Press Res, 2019, 44(5):1207-1218. https:\/\/doi.org\/10.1159\/000502647","DOI":"10.1159\/000502647"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"[83] Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, Xiao J, Wang X, Feng W, Li X. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One, 2010, 5(12):e15534. https:\/\/doi.org\/10.1371\/journal.pone.0015534","DOI":"10.1371\/journal.pone.0015534"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"[84] Woo YC, Lee CH, Fong CHY, Xu A, Tso AWK, Cheung BMY, Lam KSL. Serum fibroblast growth factor 21 is a superior biomarker to other adipokines in predicting incident diabetes. Clin Endocrinol (Oxf), 2017, 86(1):37-43. https:\/\/doi.org\/10.1111\/cen.13229","DOI":"10.1111\/cen.13229"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"[85] Lee CH, Hui EYL, Woo YC, Yeung CY, Chow WS, Yuen MMA, Fong CHY, Xu A, Lam KSL. Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria. J Clin Endocrinol Metab, 2015, 100(4):1368-1375. https:\/\/doi.org\/10.1210\/jc.2014-3465","DOI":"10.1210\/jc.2014-3465"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"[86] Chow WS, Xu A, Woo YC, Tso AWK, Cheung SCW, Fong CHY, Tse HF, Chau MT, Cheung BMY, Lam KSL. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol, 2013, 33(10):2454-2459. https:\/\/doi.org\/10.1161\/ATVBAHA.113.301599","DOI":"10.1161\/ATVBAHA.113.301599"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"[87] Wu L, Qian L, Zhang L, Zhang J, Zhou J, Li Y, Hou X, Fang Q, Li H, Jia W. Fibroblast growth factor 21 is related to atherosclerosis independent of nonalcoholic fatty liver disease and predicts atherosclerotic cardiovascular events. J Am Heart Assoc, 2020, 9(11):e015226. https:\/\/doi.org\/10.1161\/JAHA.119.015226","DOI":"10.1161\/JAHA.119.015226"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"[88] Pan Y, Hui X, Hoo RLC, Ye D, Chan CYC, Feng T, Wang Y, Lam KSL, Xu A. Adipocyte-secreted exosomal microRNA-34a inhibits M2 macrophage polarization to promote obesity-induced adipose inflammation. J Clin Invest, 2019, 129(2):834-849. https:\/\/doi.org\/10.1172\/JCI123069","DOI":"10.1172\/JCI123069"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"[89] Kusminski CM, Ghaben AL, Morley TS, Samms RJ, Adams AC, An Y, Johnson JA, Joffin N, Onodera T, Crewe C, Holland WL, Gordillo R, Scherer PE. A novel model of diabetic complications: adipocyte mitochondrial dysfunction triggers massive \u03b2-cell hyperplasia. Diabetes, 2020, 69(3):313-330. https:\/\/doi.org\/10.2337\/db19-0327","DOI":"10.2337\/db19-0327"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"[90] D\u00edaz-Delf\u00edn J, Hondares E, Iglesias R, Giralt M, Caelles C, Villarroya F. TNF-\u03b1 represses \u03b2-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology, 2012, 153(9):4238-4245. https:\/\/doi.org\/10.1210\/en.2012-1193","DOI":"10.1210\/en.2012-1193"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"[91] Badakhshi Y, Jin T. Current understanding and controversies on the clinical implications of fibroblast growth factor 21. Crit Rev Clin Lab Sci, 2021, 58(5):311-328. https:\/\/doi.org\/10.1080\/10408363.2020.1864278","DOI":"10.1080\/10408363.2020.1864278"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"[92] Ye D, Li H, Wang Y, Jia W, Zhou J, Fan J, Man K, Lo C, Wong C, Wang Y, Lam KS, Xu A. Circulating fibroblast growth factor 21 is a sensitive biomarker for severe ischemia\/reperfusion injury in patients with liver transplantation. Sci Rep, 2016, 6:19776. https:\/\/doi.org\/10.1038\/srep19776","DOI":"10.1038\/srep19776"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"[93] Ye D, Wang Y, Li H, Jia W, Man K, Lo CM, Wang Y, Lam KSL, Xu A. Fibroblast growth factor 21 protects against Acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1\u03b1-mediated antioxidant capacity in mice. Hepatology, 2014, 60(3):977-989. https:\/\/doi.org\/10.1002\/hep.27060","DOI":"10.1002\/hep.27060"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"[94] Rusli F, Deelen J, Andriyani E, Boekschoten MV, Lute C, van den Akker EB, M\u00fcller M, Beekman M, Steegenga WT. Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL\/6J mice. Sci Rep, 2016, 6:30484. https:\/\/doi.org\/10.1038\/srep30484","DOI":"10.1038\/srep30484"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"[95] He L, Deng L, Zhang Q, Guo J, Zhou J, Song W, Yuan F. Diagnostic value of CK-18, FGF-21, and related biomarker panel in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Biomed Res Int, 2017, 2017:9729107. https:\/\/doi.org\/10.1155\/2017\/9729107","DOI":"10.1155\/2017\/9729107"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"[96] El Sagheer GM, Ahmad AK, Abd-ElFattah AS, Saad ZM, Hamdi L. A study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents. Clin Exp Gastroenterol, 2018, 11:415-422. https:\/\/doi.org\/10.2147\/CEG.S173484","DOI":"10.2147\/CEG.S173484"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"[97] Wu L, Pan Q, Wu G, Qian L, Zhang J, Zhang L, Fang Q, Zang G, Wang Y, Lau G, Li H, Jia W. Diverse changes of circulating fibroblast growth factor 21 levels in hepatitis B virus-related diseases. Sci Rep, 2017, 7(1):16482. https:\/\/doi.org\/10.1038\/s41598-017-16312-6","DOI":"10.1038\/s41598-017-16312-6"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"[98] Franz K, Ost M, Otten L, Herpich C, Coleman V, Endres AS, Klaus S, M\u00fcller-Werdan U, Norman K. Higher serum levels of fibroblast growth factor 21 in old patients with cachexia. Nutrition, 2019, 63-64:81-86. https:\/\/doi.org\/10.1016\/j.nut.2018.11.004","DOI":"10.1016\/j.nut.2018.11.004"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"[99] Suomalainen A, Elo JM, Pietil\u00e4inen KH, Hakonen AH, Sevastianova K, Korpela M, Isohanni P, Marjavaara SK, Tyni T, Kiuru-Enari S, Pihko H, Darin N, \u00d5unap K, Kluijtmans LA, Paetau A, Buzkova J, Bindoff LA, Annunen-Rasila J, Uusimaa J, Rissanen A, Yki-J\u00e4rvinen H, Hirano M, Tulinius M, Smeitink J, Tyynismaa H. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol, 2011, 10(9):806-818. https:\/\/doi.org\/10.1016\/S1474-4422(11)70155-7","DOI":"10.1016\/S1474-4422(11)70155-7"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"[100] Morovat A, Weerasinghe G, Nesbitt V, Hofer M, Agnew T, Quaghebeur G, Sergeant K, Fratter C, Guha N, Mirzazadeh M, Poulton J. Use of FGF-21 as a biomarker of mitochondrial disease in clinical practice. J Clin Med, 2017, 6(8):80. https:\/\/doi.org\/10.3390\/jcm6080080","DOI":"10.3390\/jcm6080080"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"[101] Choi JR, Kim JY, Park IH, Huh JH, Kim KW, Cha SK, Park KS, Sohn JH, Park JT, Koh SB. Serum fibroblast growth factor 21 and new-onset metabolic syndrome: KoGES-ARIRANG Study. Yonsei Med J, 2018, 59(2):287-293. https:\/\/doi.org\/10.3349\/ymj.2018.59.2.287","DOI":"10.3349\/ymj.2018.59.2.287"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"[102] Ong KL, McClelland RL, Allison MA, Kokkinos J, Wu BJ, Barter PJ, Rye KA. Association of elevated circulating fibroblast growth factor 21 levels with prevalent and incident metabolic syndrome: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2019, 281:200-206. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.10.011","DOI":"10.1016\/j.atherosclerosis.2018.10.011"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"[103] Qian J, Tikk K, Weigl K, Balavarca Y, Brenner H. Fibroblast growth factor 21 as a circulating biomarker at various stages of colorectal carcinogenesis. Br J Cancer, 2018, 119(11):1374-1382. https:\/\/doi.org\/10.1038\/s41416-018-0280-x","DOI":"10.1038\/s41416-018-0280-x"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"[104] Li X, Zhu Z, Zhou T, Cao X, Lu T, Liang Y, He J, Liu C, Dou Z, Shen B. Early increases in serum FGF21 levels predict mortality of septic patients. Cytokine, 2018, 111:428-433. https:\/\/doi.org\/10.1016\/j.cyto.2018.05.020","DOI":"10.1016\/j.cyto.2018.05.020"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"[105] Anuwatmatee S, Allison MA, Shlipak MG, McClelland RL, Kramer H, Tang S, Hou L, Rye KA, Ong KL. Relationship of fibroblast growth factor 21 with kidney function and albuminuria: multi-ethnic study of atherosclerosis. Nephrol Dial Transplant, 2019, 34(6):1009-1016. https:\/\/doi.org\/10.1093\/ndt\/gfy120","DOI":"10.1093\/ndt\/gfy120"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"[106] Zhang W, Chu S, Ding W, Wang F. Serum level of fibroblast growth factor 21 is independently associated with acute myocardial infarction. PLoS One, 2015, 10(6):e0129791. https:\/\/doi.org\/10.1371\/journal.pone.0129791","DOI":"10.1371\/journal.pone.0129791"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"[107] Shen Y, Zhang X, Pan X, Xu Y, Xiong Q, Lu Z, Ma X, Bao Y, Jia W. Contribution of serum FGF21 level to the identification of left ventricular systolic dysfunction and cardiac death. Cardiovasc Diabetol, 2017, 16(1):106. https:\/\/doi.org\/10.1186\/s12933-017-0588-5","DOI":"10.1186\/s12933-017-0588-5"},{"key":"ref107","doi-asserted-by":"publisher","unstructured":"[108] Tucker W, Tucker B, Rye KA, Ong KL. Fibroblast growth factor 21 in heart failure. Heart Fail Rev, 2023, 28(1):261-272. https:\/\/doi.org\/10.1007\/s10741-022-10268-0","DOI":"10.1007\/s10741-022-10268-0"},{"key":"ref108","doi-asserted-by":"publisher","unstructured":"[109] Kliewer SA, Mangelsdorf DJ. Fibroblast growth factor 21: from pharmacology to physiology. Am J Clin Nutr, 2010, 91(1):254S-257S. https:\/\/doi.org\/10.3945\/ajcn.2009.28449B","DOI":"10.3945\/ajcn.2009.28449B"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"[110] Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J, Vos MB. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology, 2019, 69(6):2672-2682. https:\/\/doi.org\/10.1002\/hep.30251","DOI":"10.1002\/hep.30251"},{"key":"ref110","doi-asserted-by":"publisher","unstructured":"[111] Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism, 2022, 126:154925. https:\/\/doi.org\/10.1016\/j.metabol.2021.154925","DOI":"10.1016\/j.metabol.2021.154925"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"[112] Raptis DD, Mantzoros CS, Polyzos SA. Fibroblast growth factor-21 as a potential therapeutic target of nonalcoholic fatty liver disease. Ther Clin Risk Manag, 2023, 19:77-96. https:\/\/doi.org\/10.2147\/TCRM.S352008","DOI":"10.2147\/TCRM.S352008"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"[113] Harrison SA, Ruane PJ, Freilich BL, Neff G, Patil R, Behling CA, Hu C, Fong E, de Temple B, Tillman EJ, Rolph TP, Cheng A, Yale K. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat Med, 2021, 27(7):1262-1271. https:\/\/doi.org\/10.1038\/s41591-021-01425-3","DOI":"10.1038\/s41591-021-01425-3"},{"key":"ref113","doi-asserted-by":"publisher","unstructured":"[114] Charles ED, Neuschwander-Tetri BA, Pablo Frias J, Kundu S, Luo Y, Tirucherai GS, Christian R. Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study. Obesity (Silver Spring), 2019, 27(1):41-49. https:\/\/doi.org\/10.1002\/oby.22344","DOI":"10.1002\/oby.22344"},{"key":"ref114","doi-asserted-by":"publisher","unstructured":"[115] Falamarzi K, Malekpour M, Tafti MF, Azarpira N, Behboodi M, Zarei M. The role of FGF21 and its analogs on liver associated diseases. Front Med (Lausanne), 2022, 9:967375. https:\/\/doi.org\/10.3389\/fmed.2022.967375","DOI":"10.3389\/fmed.2022.967375"},{"key":"ref115","doi-asserted-by":"publisher","unstructured":"[116] Zarei M, Pizarro-Delgado J, Barroso E, Palomer X, V\u00e1zquez-Carrera M. Targeting FGF21 for the treatment of nonalcoholic steatohepatitis. Trends Pharmacol Sci, 2020, 41(3):199-208. https:\/\/doi.org\/10.1016\/j.tips.2019.12.005","DOI":"10.1016\/j.tips.2019.12.005"},{"key":"ref116","doi-asserted-by":"publisher","unstructured":"[117] Tian H, Zhang S, Liu Y, Wu Y, Zhang D. Fibroblast growth factors for nonalcoholic fatty liver disease: opportunities and challenges. Int J Mol Sci, 2023, 24(5):4583. https:\/\/doi.org\/10.3390\/ijms24054583","DOI":"10.3390\/ijms24054583"},{"key":"ref117","doi-asserted-by":"publisher","unstructured":"[118] Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, Kharitonenkov A, Bumol T, Schilske HK, Moller DE. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab, 2013, 18(3):333-340. https:\/\/doi.org\/10.1016\/j.cmet.2013.08.005","DOI":"10.1016\/j.cmet.2013.08.005"},{"key":"ref118","doi-asserted-by":"publisher","unstructured":"[119] Talukdar S, Zhou Y, Li D, Rossulek M, Dong J, Somayaji V, Weng Y, Clark R, Lanba A, Owen BM, Brenner MB, Trimmer JK, Gropp KE, Chabot JR, Erion DM, Rolph TP, Goodwin B, Calle RA. A Long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab, 2016, 23(3):427-440. https:\/\/doi.org\/10.1016\/j.cmet.2016.02.001","DOI":"10.1016\/j.cmet.2016.02.001"},{"key":"ref119","doi-asserted-by":"publisher","unstructured":"[120] Depaoli A, Phung V, Bashir MR, Morrow L, Beysen C, Yan A, Ling L, Baxter B, Luskey KL, Olefsky JM. 140-LB: NGM313, a novel activator of \u03b2-Klotho\/FGFR1c, improves insulin resistance and reduces hepatic fat in obese, nondiabetic subjects. Diabetes, 2019, 68(Suppl 1):140-LB. https:\/\/doi.org\/10.2337\/db19-140-LB","DOI":"10.2337\/db19-140-LB"},{"key":"ref120","doi-asserted-by":"publisher","unstructured":"[121] Rader DJ, Maratos-Flier E, Nguyen A, Hom D, Ferriere M, Li Y, Kompa J, Martic M, Hinder M, Basson CT, Yowe D, Diener J, Goldfine AB; CLLF580X2102 Study Team. LLF580, an FGF21 analog, reduces triglycerides and hepatic fat in obese adults with modest hypertriglyceridemia. J Clin Endocrinol Metab, 2022, 107(1):e57-e70. https:\/\/doi.org\/10.1210\/clinem\/dgab624\"","DOI":"10.1210\/clinem\/dgab624"}],"container-title":["Romanian Journal of Morphology and Embryology"],"original-title":[],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T09:10:55Z","timestamp":1723021855000},"score":1,"resource":{"primary":{"URL":"https:\/\/rjme.ro\/archive\/65\/2\/2\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":121,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,7,15]]},"published-print":{"date-parts":[[2024,7,19]]}},"URL":"https:\/\/doi.org\/10.47162\/rjme.65.2.02","relation":{},"ISSN":["1220-0522","2066-8279"],"issn-type":[{"value":"1220-0522","type":"print"},{"value":"2066-8279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]}}}